Compare Agilent Technologies Inc (A) vs Pfizer Inc (PFE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Pfizer Inc — how do they compare? Agilent Technologies Inc trades at $128.24 (market cap $37.04B), while Pfizer Inc trades at $24.25 (market cap $137.19B). The key difference: Pfizer Inc is far larger — about 3.7× Agilent Technologies Inc's market cap, and Pfizer Inc pays the higher dividend (7.15%). Which is the better fit depends on your goals.
| A | PFE | |
|---|---|---|
Market Cap | $37.04B | $137.19B |
Sector | Health | Health |
52-Week High | $157.20 | $28.56 |
52-Week Low | $110.24 | $23.29 |
Enterprise Value | $38.59B | $187.84B |
Dividend Yield | 0.78% | 7.15% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Pfizer (PFE) trades at $23.72, down 2.47% on the day, with a bearish technical signal from moving averages but recent earnings beats. The stock has a P/E of 18.11 and net income margin of 11.83%, supported by strong cash flow from operations of $11.70B in 2025. Recent news highlights pipeline progress in obesity and oncology, with dividends of $0.43 paid semi-annually.
The outlook is mixed: analyst consensus is a 'Hold' with a $27.63 price target, implying potential upside, but risks include patent cliffs and competitive pressures. Revenue has declined from pandemic peaks, yet cost controls sustain profitability. Investors may find value if pipeline catalysts materialize, though near-term volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
